MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Orca-T

  • Home
  • Orca-T
Regulatory-like FOXP3+Helios+CD4+ T Conventional Cells Correlate with T-Cell Activation After Orca-T Immunotherapy
Posted inHematology-Oncology news Pathology & Lab Medicine/Bệnh học

Regulatory-like FOXP3+Helios+CD4+ T Conventional Cells Correlate with T-Cell Activation After Orca-T Immunotherapy

Posted by By MedXY 05/29/2026
A study of leukemia patients found that Orca-T transplant therapy increases a regulatory-like CD4+FOXP3+Helios+ T-cell subset early after treatment, and this subset correlates with later T-cell activation, offering a potential biomarker for immune recovery.
Read More
Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results
Posted inClinical Updates Hematology-Oncology news

Precision T-Cell Engineering in AlloHSCT: The Orca-T Revolution and the Precision-T Phase 3 Results

Posted by By MedXY 03/19/2026
This review analyzes the Phase 3 Precision-T trial, demonstrating that Orca-T, a high-precision T-cell therapy, significantly improves chronic GVHD-free survival and reduces non-relapse mortality compared to standard-of-care prophylaxis in patients with hematologic malignancies.
Read More
  • Early Controlled Mobilisation in Radial Head Fractures Enhances Recovery Without Clinically Significant Differences
  • Innovative Polyurethane Resin Cement with Dual Antibacterial Mechanisms for Enhanced Secondary Caries Prevention
  • Remibrutinib Demonstrates Superior Efficacy and Safety over Teriflunomide in Relapsing Multiple Sclerosis: Insights from REMODEL-1 and REMODEL-2 Phase 3 Trials
  • The Community Pediatrics & Advocacy Curriculum: Standardizing Advocacy Education in Pediatric Graduate Medical Education
  • Sustained Remission and Long-Term Success: A Decade of Treat-to-Target Therapy in Early Rheumatoid Arthritis
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top